In many endocrine therapy-resistant breast cancers, the antagonist-bound ER cistrome is distinct from that of the estrogen-activated ER, thereby creating an alternative ER-transcriptome that enables disease progression [58]. This evidence concerns the gene ESR1 and breast carcinoma.